文献速递贫血与红细胞疾病

羟基脲联合沙利度胺治疗β地中海贫血的评估

Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia.
PubMed 文献 · Blood Adv · 2022-01-01

本研究为单臂非随机试验,纳入135例β地中海贫血患儿,先单用羟基脲治疗6个月,再联合沙利度胺治疗6个月。结果显示联合治疗3个月和6个月内输血量显著下降、中位血红蛋白显著升高(P < .001),89例(65.93%)为良好应答,16例(11.85%)为应答,30例(22.22%)为无应答,共报告38例不良事件,经支持治疗或暂时停药后缓解。

要点

  • 联合治疗3个月和6个月内输血量显著下降(P < .001)。
  • 联合治疗3个月和6个月内中位血红蛋白显著升高(P < .001)。
  • 89例(65.93%)良好应答,16例(11.85%)应答,30例(22.22%)无应答。

核心结论

  • 联合治疗显示出有希望的结果,可考虑用于不同的β地中海贫血患者群体。

研究设计与样本

  • 单臂非随机试验,共纳入135例β地中海贫血患儿,中位年龄6岁(四分位距3-10岁),其中男性77例(57%)、女性58例(43%)。
  • 患者先接受羟基脲单药治疗6个月,随后接受羟基脲联合沙利度胺治疗6个月。
  • 主要结局为治疗应答,通过羟基脲单药治疗期间和联合治疗期间所需的输血次数和血红蛋白水平评估。
  • 试验注册于www.clinicaltrials.gov,注册号#NCT05132270。

主要发现

  • 联合治疗3个月和6个月内输血量显著下降(P < .001)。
  • 联合治疗3个月和6个月内中位血红蛋白水平显著升高(P < .001)。
  • 89例(65.93%)为良好应答,16例(11.85%)为应答,30例(22.22%)为无应答,应答者具有不同的基因突变。
  • 共报告38例不良事件,经支持治疗或暂时停止干预后缓解。

临床怎么用

  • 作者认为联合治疗显示出有希望的结果,可考虑用于不同的β地中海贫血患者群体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transfusion-related complications and lack of resources in low-to-middle-income countries have led to a search for novel therapies to reduce the need for blood transfusions in patients with β-thalassemia. Hydroxyurea (HU) has demonstrated promising outcomes; additionally, thalidomide has also shown improvement in hemoglobin (Hb) levels for patients with β-thalassemia in some studies. This study presents the findings of a single-arm nonrandomized trial to evaluate the efficacy of combination therapy of HU and thalidomide in children with β-thalassemia. A total of 135 patients (median age, 6 [interquartile range, 3-10] years), 77 (57%) males and 58 (43%) females, were followed first using HU alone, for 6 months, and then using the combination of HU and thalidomide for another 6 months. The primary outcome was a response to therapy, as measured by the number of transfusions required and Hb levels, for patients while receiving HU alone and then while using the combination therapy. Study findings showed a significant decline in blood transfusion volume (P < .001) and a significant increase in median Hb levels within 3 and 6 months of the combination therapy (P < .001). Eighty-nine (65.93%) participants were good responders, 16 (11.85%) were responders, and 30 (22.22%) were nonresponders, whereas the responders had variable genetic mutations. A total of 38 adverse events were reported that resolved on supportive treatment or temporary hold of the intervention. The combination therapy demonstrated promising results and could be considered for a diverse patient population with β-thalassemia. This trial was registered at www.clinicaltrials.gov as #NCT05132270.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ansari SH, Ansari I, Wasim M, et al. Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia. Blood Adv. 2022. PMID: 35477175. doi:10.1182/bloodadvances.2022007031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。